Evotec SE
EVO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for EVO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EVO
Evotec SE is a precision medicine company that leverages a modality-agnostic platform spanning small molecules, biologics, RNA-targeting approaches, and cell therapy to discover and develop drug candidates, generating revenue through services, milestones, and royalties.
Key risk: Drug development uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$678.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2024.
Tracking 1 clinical trial for Evotec SE.
Evotec SE is a precision medicine company that leverages a modality-agnostic platform spanning small molecules, biologics, RNA-targeting approaches, and cell therapy to discover and develop drug candidates, generating revenue through services, milestones, and royalties.
- Evotec's integrated platform enables iPSC-based disease modeling and drug screening at an industrialized scale [sec · filed 2026-04-08].
- As of December 31, 2024, the partnered pipeline included more than 140 assets, with one drug approved in China and six projects in Phase I [sec · filed 2025-04-17].
- Revenue from third parties in 2023 and 2024 included 0.6% and 0.4% from milestone payments, respectively, with no mentionable royalty contribution [sec · filed 2025-04-17].
- As of 2024-12-31, Evotec reported cash & equivalents of $306.4M, total revenue of $797.0M, and a net loss of -$196.1M [sec].
- The company's pipeline has expanded from exclusively small molecules in 2015 to include cell and gene therapy, biologics, and multi-modality projects by 2023 [sec · filed 2024-08-14].
What works
- Evotec's modality-agnostic platform covers small molecules, biologics, RNA-targeting, and cell therapy, maximizing the potential of its integrated technology [sec · filed 2026-04-08].
- The company's iPSC platform is considered industry-leading for disease modeling and drug screening, potentially reducing clinical trial attrition rates [sec · filed 2026-04-08].
- Evotec has a large partnered pipeline of over 140 assets, providing multiple opportunities for milestone and royalty revenue [sec · filed 2025-04-17].
- Market trends toward external innovation and capital-efficient R&D are expected to drive demand for Evotec's services and collaborations [sec · filed 2025-04-17].
What to weigh
- Evotec's business is subject to significant challenges facing the pharmaceutical and biotechnology industries, including uncertain drug development outcomes [sec · filed 2026-04-08].
- Revenue from milestones and royalties is inherently uncertain, as it depends on successful achievement of scientific or regulatory events [sec · filed 2025-04-17].
- The company reported a net loss of -$196.1M for the year ended 2024-12-31, indicating ongoing profitability challenges [sec].
- Failure by licensees to develop or commercialize pipeline assets in a timely manner could materially affect Evotec's revenue [sec · filed 2025-04-17].
From the filings
Quoted directly from source documents.
Evotec's platform enables iPSC-based disease modeling at scale.
“enables iPSC-based disease modelling and drug screening at an industrialized scale.”
SEC filings · April 8, 2026
The company's pipeline includes more than 140 partnered assets.
“Our pipeline currently includes more than 140 partnered assets.”
SEC filings · April 17, 2025
Milestone and royalty revenue is a key part of the growth strategy.
“of our growth strategy is the generation of milestones and royalties.”
SEC filings · April 17, 2025
Evotec's business faces risks from industry challenges and uncertain drug development.
“Our business is subject to the significant and increasing challenges that face the pharmaceutical and biotechnology industries”
SEC filings · April 8, 2026
Risks & what to watch (4)›
Key risks
- Drug development uncertainty — Success in innovation and drug development is highly uncertain, impacting pipeline progress and revenue [sec · filed 2026-04-08].
- Revenue concentration on milestones — Milestone and royalty revenue is unpredictable and tied to successful scientific or regulatory events [sec · filed 2025-04-17].
- Profitability and net loss — Evotec reported a net loss of -$196.1M for fiscal year 2024, indicating ongoing profitability challenges [sec].
- Dependence on partners — Failure by licensees to develop or commercialize assets could materially affect Evotec's financial results [sec · filed 2025-04-17].
What to watch
- Progress of the six partnered pipeline projects in Phase I and the one approved drug in China [sec · filed 2025-04-17].
- Ability to convert the large partnered pipeline (over 140 assets) into milestone and royalty revenue [sec · filed 2025-04-17].
- Trends in external R&D demand from pharmaceutical and biotech industries [sec · filed 2025-04-17].
- Evotec's path to profitability given the recent net loss [sec].
Sources: SEC filings · Generated August 28, 2026 · How we verify sources →
Run Evotec SE through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Evotec SE facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 1.01
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
43
Total value held
$5.8M
| Holder | Shares | Value |
|---|---|---|
| wcm investment management, llc | 627,260 | $1.5M |
| abc arbitrage sa | 509,050 | $1.3M |
| optiver holding b.v. | 283,576 | $709K |
| morgan stanley | 259,744 | $649K |
| envestnet asset management inc | 119,409 | $299K |
| millennium management llc | 99,568 | $249K |
| citadel advisors llc | 87,180 | $218K |
| pathstone holdings, llc | 34,127 | $85K |
| fore capital, llc | 31,355 | $78K |
| snowden capital advisors llc | 24,409 | $61K |
Showing top 10 of 43 institutional holders of Evotec SE. Open the full 13F history after sign-in.
Short Interest
as of Apr 24, 2026- % of float
- 0.1%
- Days to cover
- 2.7
- Shares short
- 349,478
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EVO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Evotec SE?
Evotec SE is a precision medicine company that leverages a modality-agnostic platform spanning small molecules, biologics, RNA-targeting approaches, and cell therapy to discover and develop drug candidates, generating revenue through services, milestones, and royalties.
Who is the CEO of Evotec SE?
Dr. Christian Wojczewski Ph.D. is the chief executive officer of Evotec SE (EVO).
Where is Evotec SE headquartered?
Evotec SE (EVO) is headquartered in Hamburg, Germany.
What therapeutic areas does Evotec SE focus on?
Evotec SE develops therapies across Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.